Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure

Tekin, Abdullah; Sezgin, Nurzen; Katırcıbaşı, Mahmut Tuna; Tekin, Göknur; Çölkesen, Yücel; Sezgin, Alpay Turan; Müderrisoğlu, Haldun

doi:10.1097/mca.0b013e32830d27d2

Cited by 7 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 35 (83%) studies, patients had a diagnosis of type 2 diabetes, in five (12%), patients had a diagnosis of type 1 or 2 diabetes, 55 70 71 79 80 and in two (5%) studies, patients had a diagnosis of type 1 diabetes only. 63 74 Of the 22 (49%) studies that reported the average length of the diagnosis of diabetes, the median was 8 years (range 4-11, interquartile range 7).…”

Section: Resultsmentioning

confidence: 99%

“…Hence to investigate the role of baseline scores, an individual patient data meta-analysis would be required. We tried contacting the authors for their baseline data, but only three responded 387380. We recommend that these data are reported in future trials to allow the adjusted baseline change scores to be used instead of the final scores.…”

Section: Discussionmentioning

confidence: 99%

“…We tried contacting the authors for their baseline data, but only three responded. 38 73 80 We recommend that these data are reported in future trials to allow the adjusted baseline change scores to be used instead of the final scores.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis

Hodkinson

Tsimpida

Kontopantelis

et al. 2022

BMJ

View full text Add to dashboard Cite

ObjectiveTo compare the efficacy of different statin treatments by intensity on levels of non-high density lipoprotein cholesterol (non-HDL-C) for the prevention of cardiovascular disease in people with diabetes.DesignSystematic review and network meta-analysis.Data sourcesMedline, Cochrane Central Register of Controlled Trials, and Embase from inception to 1 December 2021.Review methodsRandomised controlled trials comparing different types and intensities of statins, including placebo, in adults with type 1 or type 2 diabetes mellitus were included. The primary outcome was changes in levels of non-HDL-C, calculated from measures of total cholesterol and HDL-C. Secondary outcomes were changes in levels of low density lipoprotein cholesterol (LDL-C) and total cholesterol, three point major cardiovascular events (non-fatal stroke, non-fatal myocardial infarction, and death related to cardiovascular disease), and discontinuations because of adverse events. A bayesian network meta-analysis of statin intensity (low, moderate, or high) with random effects evaluated the treatment effect on non-HDL-C by mean differences and 95% credible intervals. Subgroup analysis of patients at greater risk of major cardiovascular events was compared with patients at low or moderate risk. The confidence in network meta-analysis (CINeMA) framework was applied to determine the certainty of evidence.ResultsIn 42 randomised controlled trials involving 20 193 adults, 11 698 were included in the meta-analysis. Compared with placebo, the greatest reductions in levels of non-HDL-C were seen with rosuvastatin at high (−2.31 mmol/L, 95% credible interval −3.39 to −1.21) and moderate (−2.27, −3.00 to −1.49) intensities, and simvastatin (−2.26, −2.99 to −1.51) and atorvastatin (−2.20, −2.69 to −1.70) at high intensity. Atorvastatin and simvastatin at any intensity and pravastatin at low intensity were also effective in reducing levels of non-HDL-C. In 4670 patients at greater risk of a major cardiovascular events, atorvastatin at high intensity showed the largest reduction in levels of non-HDL-C (−1.98, −4.16 to 0.26, surface under the cumulative ranking curve 64%). Simvastatin (−1.93, −2.63 to −1.21) and rosuvastatin (−1.76, −2.37 to −1.15) at high intensity were the most effective treatment options for reducing LDL-C. Significant reductions in non-fatal myocardial infarction were found for atorvastatin at moderate intensity compared with placebo (relative risk=0.57, confidence interval 0.43 to 0.76, n=4 studies). No significant differences were found for discontinuations, non-fatal stroke, and cardiovascular deaths.ConclusionsThis network meta-analysis indicated that rosuvastatin, at moderate and high intensity doses, and simvastatin and atorvastatin, at high intensity doses, were most effective at moderately reducing levels of non-HDL-C in patients with diabetes. Given the potential improvement in accuracy in predicting cardiovascular disease when reduction in levels of non-HDL-C is used as the primary target, these findings provide guidance on which statin types and intensities are most effective by reducing non-HDL-C in patients with diabetes.Systematic review registrationPROSPERO CRD42021258819.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis

Hodkinson

Tsimpida

Kontopantelis

et al. 2022

BMJ

View full text Add to dashboard Cite

show abstract

“…The level of IL-10 was shown to be elevated in the plasma of unstable angina patients using statins [20]. Studies with heart failure patients also supported the elevation of IL-10 with statin usage [21]. While IL-10 shows inhibitory features on MMPs, enzyme myeloperoxidase can oxidatively activate MMP-8 and MMP-9 and contributes to the periodontal destruction and can generate reactive oxygen species [22].…”

Section: Introductionmentioning

confidence: 92%

Statins and IL-1β, IL-10, and MPO Levels in Gingival Crevicular Fluid: Preliminary Results

et al. 2016

View full text Add to dashboard Cite

Statins possess a wide variety of pleiotropic properties that are independent of their lipid-lowering abilities such as attenuating inflammation, oxidative stress, coagulation, platelet aggregation and stimulating bone formation. The aim of the study is to evaluate the effect of statins on clinical periodontal parameters and gingival crevicular fluid (GCF) levels of IL-1β, IL-10, and myeloperoxidase (MPO) in inflammatory periodontal diseases. Seventy-nine subjects with hyperlipidemia and 48 systemically healthy controls (C) were included. Hyperlipidemic patients were either given a diet (HD) or prescribed statin (HS). Patients were classified into three subgroups as those who were periodontally healthy (h), who had gingivitis (g), or who had chronic periodontitis (p). Blood samples were collected for the measurement of lipid profiles. Plaque index (PI), gingival index (GI), probing pocket depth (PD), clinical attachment level (CAL), and percentage of bleeding on probing (BOP) were recorded. Gingival crevicular fluid levels of IL-1β, IL-10, and MPO were measured in order to determine the anti-inflammatory and antioxidant effects of statins. Probing depth values of the HSp group were significantly lower than those of the Cp group. Percentage of BOP of the HSg group was significantly lower than those of the HDg and Cg groups. While the IL-1β level of the HSp group was significantly lower than that of the HDp group, IL-10 levels of the HSg group were significantly higher than those of the HDg group. MPO levels were significantly lower in the HSg group when compared to those in the HDg and Cg groups. Statin use decreased the IL-1β and MPO levels and enhanced IL-10 in GCF. It can be suggested that statins may attenuate periodontal inflammation and progression of periodontal inflammation.

show abstract

Fluvastatin for lowering lipids

Adams

Sekhon

Tsang

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Fluvastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose-dependent linear fashion. Based on the effect on LDL cholesterol, fluvastatin is 12-fold less potent than atorvastatin and 46-fold less potent than rosuvastatin. This review did not provide a good estimate of the incidence of harms associated with fluvastatin because of the short duration of the trials and the lack of reporting of adverse effects in 56% of the placebo-controlled trials.

show abstract

Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure

Abstract: Fluvastatin therapy might lead to an increase in plasma IL-10 levels and an associated improvement in vagal tonus as assessed by HRR at 1 min in patients with HF. These findings might partly explain the possible benefit observed in statin trials.

Cited by 7 publications

References 56 publications

Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis

Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis

Statins and IL-1β, IL-10, and MPO Levels in Gingival Crevicular Fluid: Preliminary Results

Fluvastatin for lowering lipids

Contact Info

Product

Resources

About